Authors

Amanda Przespolewski, DO

Latest:

Notable Advancements in Treatment for ALL

Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.

Yovanni Casablanca, MD

Latest:

Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical Cancer

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Tarun Wasil, MBBS, FACP

Latest:

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

Andrei H. Iagaru, MD

Latest:

Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate Cancer

Andrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.

Monica Balzarotti, MD

Latest:

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Denise M. Wolf, PhD

Latest:

Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast Cancer

Denise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.

Madappa Kundranda, MD,PhD

Latest:

Dr. Kundranda on the Sequencing of Second-Line Therapies in HCC

Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.

Adrienne A. Boire, MD, PhD

Latest:

A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD

Drs Camidge and Boire discuss Dr Boire's path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.

Chris Danes, Scientific Director, US Medical Affairs for Lung Cancer, Takeda Oncology

Latest:

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

Jeff Michalski, MD, MBA, FASTRO

Latest:

Dr. Michalski on the Goals ASTRO in Radiation Oncology

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

Kanak Parmar, MD

Latest:

Immunotherapy Paves Path for New Standards of Care in Gastroesophageal Cancers

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

Jonathan A. Chatzkel, MD

Latest:

Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold Tumors

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Alain Charles Borczuk, MD

Latest:

Dr Borczuk on Currently Offered Gene Testing for Patients With Lung Cancer

Alain Charles Borczuk, MD, discusses gene testing that may be offered for patients with lung cancer.

Curtis Lachowiez, MD

Latest:

Best Practices for Virtual Conference Presentations

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center

Latest:

Using Systemic Therapy to Treat HER2+ Breast Cancer

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Vishal A. Patel, MD, FAAD, FACMS, GW Cancer Center

Latest:

Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCC

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

Jon O. Ebbert, MD, Mayo Clinic

Latest:

Future of Multi-Cancer Early Detection: A Recap and Horizon

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Ana Christina Garrido-Castro, MD

Latest:

Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Burton Eliot Appel, MD

Latest:

Dr Appel on the Significance of International Childhood Cancer Day

Burton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.

John Chan, MD

Latest:

Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs

Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.